Teva Sues Kyowa Hakko Over Pravachol Patent Infringement
This article was originally published in PharmAsia News
Israel's Teva Pharmaceutical Industries, the world's largest maker of generic drugs, filed a suit against Kyowa Hakko Kogyo on grounds the Japanese firm violated a patent held by Teva's Hungarian subsidiary. The suit involves a compound for an anti-cholesterol Pravachol (pravastatin sodium), patented in the United States by Bristol Myers Squibb, and for which the Teva subsidiary received a Japanese patent in 2005. Kyowa Hakko said it began producing the raw material in 2003 as the basis for a generic drug it now sells on the domestic Japanese market. The year before, a forerunner of Daiichi Sankyo had owned the Pravachol compound until its patent expired in 2002. (Click here for more - may require a subscription
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.